Novo Nordisk Shares Drop as Post-Wegovy Growth Strategy Fails to Alleviate Competition Concerns
Novo Nordisk (NYSE:NVO) shares fell nearly 7% following the company's long-term growth strategy presentation at a capital markets day in London, which failed to reassure investors about its ability to maintain dominance in the obesity drug market. The firm outlined plans for revenue growth aligned with industry peers by 2030 and aims to launch over five blockbuster drugs during that period. However, this guidance was seen as below expectations given Novo Nordisk's historical performance driven largely by Wegovy and Ozempic. The company highlighted the looming patent expiry of semaglutide in the U.S. market in 2032—a key ingredient driving over half its sales last year—which has intensified concerns about competition from other pharmaceutical firms entering the space. CEO Mike Doustdar acknowledged these challenges but emphasized a strategy to diversify into blood disorders, liver disease, and cardiovascular conditions. Meanwhile, Eli Lilly (NYSE:LLY) saw minor declines while Viking Therapeutics (NASDAQ:VKTX), seen as an emerging competitor in obesity treatments, edged higher.
Topics: capital markets day GLP-1 competitors obesity drugs pharmaceuticals